

1/16




FIGURE 1

2/16




FIGURE 2

3/16




FIGURE 3

4/16




FIGURE 4

5/16




FIGURE 5

6/16

Interleukine-2 receptor



IL-2 AND IP130 SEQUENCE (α -HELICES ARE BOXED)

FIGURE 6

7/16




FIGURE 7

8/16




FIGURE 8A




FIGURE 8B




FIGURE 8C




FIGURE 8D

9/16




FIGURE 9A





FIGURE 9B

10/16

1 A P T T S S T K K T Q L Q L E H L L D L Q M I L N G I N N		10 20 30		Main molecular species	Activity
1 A P T T S S T K K T Q L Q L E H L L D L Q M I L N G I N N		10 20 30			
1 30				Tetramer (4M-8M, $K_d=30-100\mu\text{M}$) /Octamer	+++
10 30				Dimer (1M-2M, $K_d=0.2\mu\text{M}$) /Tetramer (2M-4M, $K_d=100\mu\text{M}$)	++
1 22				!	-
1 10					-
5 15				Dimer (1M-2M, $K_d=50\mu\text{M}$) (2M-4M, $K_d=1.4\text{mM}$)	-
10 20				Dimer (1M-2m, $K_d=113\mu\text{M}$)	-
10 20				Monomer	ND
20 30				Monomer	+

FIGURE 10

11/16



IP130

IP130





FIGURE 11

12/16



13/16





FIGURE 13

14/16



Model of transduction pathway induced by IP130

FIGURE 14

IL-2 receptor and its major signal transduction pathway

15/16


NK cells (CD56⁺) entering in S+G2/M phases after IP130 stimulation
(synergy with IL-2)

Treatment		J31	J32	J33
IL-2 50 nM		14	12	14
	IP130 60 μ M	0	17	≤ 5
	IP130 120 μ M	0	14	< 5
IL-2 50 nM +	IP130 60 μ M	26	21	7
IL-2 50 nM +	IP130 120 μ M	28	28	28


FIGURE 15

16/16



Stimulation
3 Days



Effector / target = 10



6 Days



9 Days





FIGURE 16